2-Phenylethynyl-butyltellurium attenuates amyloid-β peptide(25-35)-induced learning and memory impairments in mice

Journal of Neuroscience Research

Volumn 91, Issue 6, 2013, Pages 848-853

  Souza, Ana Cristina Guerra ^a   Sari, Marcel Henrique Marcondes ^a   Pinton, Simone ^a   Luchese, Cristiane ^b   Neto, José Sebastião Santos ^a   Nogueira, Cristina Wayne ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b CENTRO UNIVERSITÁRIO FRANCISCANO   (Brazil)

Author keywords

Alzheimer's disease; Amyloid 25 35; Memory; Organotellurium; Tellurium

Indexed keywords

2 PHENYLETHYNYL BUTYLTELLURIUM; AMYLOID BETA PROTEIN[25-35]; TELLURIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR; LATENT PERIOD; LEARNING; LOCOMOTION; LONG TERM MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; TREATMENT DURATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; MICE; NEUROPROTECTIVE AGENTS; ORGANOMETALLIC COMPOUNDS; PEPTIDE FRAGMENTS;

EID: 84876490620     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23211     Document Type: Article

References (37)

1. Ávila DS, Colle D, Gubert P, Palma AS, Puntel G, Manarin F, Noremberg S, Nascimento PC, Aschner M, Rocha JB, Soares FA. 2010. A possible neuroprotective action of a vinylic telluride against Mn-induced neurotoxicity. Toxicol Sci 115:194-201.
2. Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER. 1999. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96:5280-5285.
3. Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer's disease Lancet 368:387-403.
4. Christen Y. 2000. Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:621-629.
5. Coleman P, Federoff H, Kurlan R. 2004. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63:1155-1162.
6. Comasseto JV, Menezes PH, Stefani HA, Zeni G, Braga AL. 1996. Addition of hydrogen halides to acetylenic selenides. Synthesis of 1-halo-1-selenoalkenes. Tetrahedron 52:9687-9702.
7. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. 2007. Caffeine and adenosine A2a receptor antagonists prevent β-amyloid(25-35)-induced cognitive deficits in mice. Exp Neurol 203:241-245.
8. D'Hooge R, De Deyn PP. 2001. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 36:60-90.
9. Haley TJ, McCormick WG. 1957. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12-15.
10. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
11. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PG, Nyakas C. 1999. Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 23:963-1008.
12. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122.
13. Klein WL, Stine WB Jr, Teplow DB. 2004. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease Neurobiol Aging 25:569-580.
14. Kubo T, Nishimura S, Kumagae Y, Kaneko I. 2002. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70:474-483.
15. Laursen SE, Belknap JK. 1986. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16:355-357.
16. Morris RG. 1984. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
17. Mount C, Downtown C. 2006. Alzheimer's disease: progress or profit? Nat Med 12:780-784.
18. Okun E, Arumugam TV, Tang SC, Gleichmann M, Albeck M, Sredni B, Mattson MP. 2007. The organotellurium compound ammonium trichloro(dioxoethylene-o, o′) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J Neurochem 102:1232-1241.
19. Persike DS, Cunha RLOR, Juliano L, Silva IR, Rosim FE, Vignolli T, Dona F, Cavalheiro EA, Fernandes MJ. 2008. Protective effect of the organotellurane RT-07 in pilocarpine-induced status epilepticus. Neurobiol Dis 31:120-126.
20. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265.
21. Pinton S, da Rocha JT, Zeni G, Nogueira CW. 2010. Organoselenium improves memory decline in mice: involvement of acetylcholinesterase activity. Neurosci Lett 472:56-60.
22. Pinton S, da Rocha JT, Gai BM, Prigol M, da Rosa LV, Nogueria CW. 2011. Neuroprotector effect of p, p′-methoxyl-diphenyl diselenide in a model of sporadic dementia of Alzheimer's type in mice: contribution of antioxidant mechanism. Cell Biochem Funct 29:235-243.
23. Rosa RM, Flores DG, Appelt HR, Braga AL, Henriques JAP, Roesler R. 2003. Facilitation of long-term object recognition memory by pretraining administration of diphenyl diselenide in mice. Neurosci Lett 341:217-220.
24. Sakaguchi M, Koseki M, Wakamatsu M, Matsumura E. 2006. Effects of systemic administration of β-casomorphin-5 on learning and memory in mice. Eur J Pharmacol 530:81-87.
25. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
26. Schmitt U, Hiemke C. 1998. Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol Biochem Behav 59:807-811.
27. Selkoe DJ. 2004. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6:1054-1061.
28. Souza ACG, Luchese C, Neto JSS, Nogueira CW. 2009. Antioxidant effect of a novel class of telluroacetilene compounds: studies in vitro and in vivo. Life Sci 84:351-357.
29. Souza ACG, Bruning CA, Leite MR, Zeni G, Nogueira CW. 2010. Diphenyl diselenide improves scopolamine-induced memory impairment in mice. Behav Pharmacol 21:556-562.
30. Souza ACG, Acker CI, Gai BM, Neto JSS, Nogueira CW. 2012. 2-Phenylethynyl-butyltellurium improves memory in mice. Neurochem Int 60:409-414.
31. Stangherlin EC, Luchese C, Pinton S, Rocha JB, Nogueira CW. 2008. Subchronic exposure to diphenyl diselenide enhances acquisition and retention of spatial memory in rats. Brain Res 1201:106-113.
32. Um MY, Choi WH, Aan JY, Kim SR, Ha TY. 2006. Protective effect of Polygonum multiflorum Thunb on amyloid β-peptide25-35 induced cognitive deficits in mice. J Ethnopharmacol 104:144-148.
33. Walsh RN, Cummins RA. 1976. The open-field test: a critical review. Psychol Bull 83:482-504.
34. Wang HH, Chou CJ, Liao JF, Chen CF. 2001. Dehydroevodiamine attenuates β-amyloid peptide-induced amnesia in mice. Eur J Pharmacol 413:221-225.
35. Wang XY, Chen J, Zhang JT. 2001. Effect of ginsenoside Rg 1 on learning and memory impairment induced by beta-amyloid peptide(25-35) and its mechanism of action. Yao Xue Xue Bao 36:1-4.
36. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK. 2001. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133:89-96.
37. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G. 2004. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000:32-39.